BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ALN-RSV01: Completed Phase IIb enrollment

Alnylam completed enrollment of about 90 RSV-infected lung transplant patients in the double-blind, placebo-controlled, international Phase IIb trial evaluating 0.6 mg/kg inhaled ALN-RSV01 once daily for 5 days. The compound is delivered with the eFlow Nebulizer System from ...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >